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Abstract
In this study using genetic approaches in mouse we demonstrate that the secreted protein Wise plays essential roles in
regulating early bone formation through its ability to modulate Wnt signaling via interactions with the Lrp5 co-receptor. In
Wise2/2 mutant mice we find an increase in the rate of osteoblast proliferation and a transient increase in bone mineral
density. This change in proliferation is dependent upon Lrp5, as Wise;Lrp5 double mutants have normal bone mass. This
suggests that Wise serves as a negative modulator of Wnt signaling in active osteoblasts. Wise and the closely related
protein Sclerostin (Sost) are expressed in osteoblast cells during temporally distinct early and late phases in a manner
consistent with the temporal onset of their respective increased bone density phenotypes. These data suggest that Wise
and Sost may have common roles in regulating bone development through their ability to control the balance of Wnt
signaling. We find that Wise is also required to potentiate proliferation in chondrocytes, serving as a potential positive
modulator of Wnt activity. Our analyses demonstrate that Wise plays a key role in processes that control the number of
osteoblasts and chondrocytes during bone homeostasis and provide important insight into mechanisms regulating the Wnt
pathway during skeletal development.
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Introduction
Recent studies have shown that canonical Wnt signaling plays
multiple roles during skeletal development, including the genesis of
chondrocytes, osteoblasts and osteoclasts [1–4]. The Wnt pathway
is important for the early fate decisions taken by the osteochondro-
progenitor cell, where high levels of b-catenin promote the
osteoblast lineage and low levels of b-catenin lead to the
chondrocyte lineage [1,3]. Later during skeletal development,
Wnt activity is also important for chondrocyte proliferation and
for the regulation of bone homeostasis [2,5]. Bone homeostasis is a
finely controlled process whereby a balance is maintained between
cells responsible for building bone (osteoblasts) and cells respon-
sible for removing bone (osteoclasts). Wnt signaling in osteoblasts is
required for their proliferation and maturation, and for the
expression of the osteoclast differentiation antagonist, osteoprote-
gerin (OPG) [2]. Thus, the Wnt pathway has a series of direct and
indirect inputs into the control of both osteoblastogenesis and
osteoclastogenesis, and as a consequence maintaining the proper
levels of Wnt activity is critical for bone homeostasis.
The large number of extracellular components associated with
Wnt signaling in a variety of tissue contexts, makes this pathway
highly complex in nature - 19 Wnt ligands, 10 Frizzled receptors,
2 LRP co-receptors, and the 12 soluble inhibitors (sFRP, Dkk,
Sost, and Wise). Yet, the complexity of these inputs provides
diverse means for tightly controlling the output and balance of
Wnt signal transduction. This also makes it a challenge to define
the specific cohort of actual modifiers of Wnt signaling employed
in any given tissue or context, such as skeletal development. In
light of these difficulties, studies examining the role of the Wnt
pathway during bone formation and homeostasis have focused on
the more conserved intracellular components of this pathway, and
taken advantage of the fact that the canonical Wnt pathway
converges upon b-catenin for its activity. Due to the critical role of
b-catenin in many tissues and developmental processes, genetic
studies involving b-catenin have depended upon conditional mouse
mutants to investigate its role as a component of the Wnt pathway
in skeletal development. These analyses have been complicated
because results are dependent upon the timing of b-catenin
inactivation or activation during osteoblastogenesis. For example,
two studies demonstrate a role for Wnt signaling during
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osteoblastogenesis by conditionally modulating b-catenin and/or
APC, another conserved intracellular Wnt pathway molecule
[2,4]. Both studies concluded that a deletion of b-catenin leads to
osteoporosis (low bone mass) and activation of b-catenin leads to
osteopetrosis (high bone mass). However, one of the studies
reported that a deletion of b-catenin resulted in increased RANK-L
and a decrease in osteoblast number [4], while the other found
that a loss of b-catenin function leads to an increase in osteoclast
number, and no change in osteoblast number [2]. It is important
to note that both studies concluded that the loss-of-b-catenin
function resulted in defects in bone resorption rather than bone
formation, which contrasts with the bone formation defects
observed upon mutation of the mouse Lrp5 gene [6]. Recessive
loss-of-function mutations that map to the Human LRP5 gene
cause osteoporosis pseudoglioma (OPPG) syndrome, which is
characterized by low bone mass, while a dominant gain-of-
function mutation results in the High Bone Mass (HBM) trait [6–
12]. Additional amino acid mutations have been mapped to the
first propeller region of LRP5 which also leads to HBM disease
[13–16]. Although there is a suggestion that Lrp5 can under
certain circumstances modulate bone density through serotonin
synthesis in the duodenum [17], more recent studies using mice
with osteocyte-specific expression of Lrp5 alleles clearly indicates
that Lrp5 functions directly in these cells to effect changes in bone
mass via canonical Wnt signaling [18].
The results in these studies suggest that precise or dynamic
maintenance of the levels of activity of the Wnt pathway are
essential to potentiate its diverse functions in skeletal development
and highlight the need to understand the actual molecular
mechanisms that modulate this pathway. In this regard, using a
functional screen we previously isolated a gene, Wise, encoding a
novel and highly-conserved secreted protein. In vitro assays
revealed that Wise binds to the Wnt co-receptors Lrp5 or Lrp6
and in Xenopus assays can activate and inhibit Wnt signaling in a
context-dependent manner [19]. In addition, Wise (also known as,
USAG-1, Ectodin, and SOSTDC1) has also been shown, by us
and others, to selectively bind BMP ligands and inhibit their
signaling in culture assays [20–22]. Hence, Wise posses the
biochemical ability to potentially modulate both Wnt and BMP
signaling. This is interesting in relation to bone development
because Wise shares high homology to Sclerostin (SOST) and
together they define a novel sub-group of cysteine knot proteins
[19,20,23]. SOST, positionally cloned as the gene causing
Sclerosteosis is a regulator of bone density [24–26]. Based on its
weak similarity to the DAN and CCN family of cystein knot
proteins, which themselves bind BMPs, Sclerostin has been
postulated to exert its function in regulating bone density via its
biochemical ability to bind BMPs and inhibit signaling [25,27,28].
However, we and others have shown that both Wise and
Sclerostin can function to inhibit Wnt signaling in in vitro assays by
binding to Lrp5 or Lrp6 [19,20,23,29]. In vivo Wise modulates
Wnt-dependent tooth number and patterning through Lrp5 and
Lrp6 in combination with a negative feedback loop between Wnt
and SHH signaling [30]. Wise also modulates Wnt signaling in the
formation and patterning of skin appendage placodes through
Lrp4 [31]. A more recent study reported that Wise (together with
Sclerostin) coordinated digit number through Wnt-dependent
misregulation of SHH signaling, suggesting a relationship between
Wise function and skeletal development [32]. However, no
analyses or comments were made detailing any other skeletal
defects. Loss-of-function mutations in the human LRP5 gene result
in a recessive low bone mass syndrome (OPPG) while a G171V
substitution results in a dominant high bone mass (HBM) trait
[10,11]. This opens the possibility that Wise and Sost may regulate
bone density in a common manner based on their abilities to
modulate Wnt signaling.
To address this question we have used genetic analyses in the
mouse to investigate the roles of Wise in bone development. Here
we report that Wise has multiple functions in regulating
developmental aspects of bone formation through its interaction
with the Wnt co-receptor Lrp5. Specifically, we show that Wise
modulates chondrocyte and osteoblast rates of proliferation in an
Lrp5-dependent manner. We also find that Wise and Sost are
differentially expressed in osteoblast cells during temporally
distinct phases in a manner consistent with the onset of their
respective increased bone density phenotypes. Our findings
strongly suggest that Wise and Sost are key modulators of bone
development through the ability of their encoded proteins to
interact with Lrps and control the balance or levels of Wnt
signaling.
Materials and Methods
Wise Mutant Mouse (129 Sv/EV & C57BL6)
A neoLacZ cassette containing stop codons at the 39 end was
inserted into exon1 of Wise at the SmaI site in a genomic fragment
isolated from a 129 Sv/EV mouse BAC. The modified BAC was
then used for homologous recombination after electroporation
into either 129 Sv/EV or C57BL6 mouse ES cells. Specific
integrants were selected from Southern analysis using a 39 probe
within exon 2 of Wise. EcoRI digests yielded either a 6.8 Kb
fragment associated with homologous recombination, or a 9 Kb
fragment associated with a random integration event. The mice
were genotyped using the following primers (59-39 orientation);
wildtype forward primer (MA3) ‘‘GCAAGGGGGAAAGAA-
TAAGCG’’; wildtype reverse primer (MB33) ‘‘GATCCAGTC-
CAGTGCTACTG’’; and Wise mutant reverse primer (BG3C2)
‘‘CATCTGCCAGTTTGAGGGGA’’. The resulting PCR products
are a wildtype band at 250 bp and Wise mutant band at 401 bp.
Characterization of mutant animals revealed that for unknown
reasons the LacZ gene in the targeting site is not expressed.
Immunochemistry (IHC)
Mouse femurs were harvested from post natal day 0 (P0), fixed
in 4% paraformaldhyde and processed for standard paraffin
sectioning. H&E was carried out using standard histological
techniques. IHC was preformed using PBS (with or without
Triton) and 10% goat serum [16]. The primary antibody was a
custom made murine Wise anti-peptide rabbit polyclonal antibody
(1:200) [20]. Five male animals were used for each genotype and
stage unless stated otherwise. Control samples that included no
primary antibody and pre-immune sera instead of primary
antibody were used to determine specificity of all antibodies [16].
Bone Density
Bone densitometry was measured on whole body using a
PIXImus mouse densitometer (GE medical systems). Bone mineral
and body composition were measured using Dual X-ray absorp-
tiometry (DEXA). The whole mouse, including hands and feet,
were carefully placed within the PIXImus data square. A
minimum of five animals from each sex, mouse strain and
genotype were used per stage unless stated otherwise. Two tailed
student T-Test statistics was used with a confidence interval of p,
0.05 to identify level of significance.
TRAP and ALP
Alkaline phosphatase (ALP) staining was preformed on cryosec-
tioned E14.5 mouse femurs. ALP staining was carried out for 15
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minutes at Room Temperature (RT) in 100 mM Tris-maleate
(pH 9,2), Naphthol As-MX phosphate and Fast red TR. For ALP
on Mouse femurs at P0, plastic sections were used instead of
cryosections, and NBT/BCIP instead of fast red. TRAP (tartrate
resistant acid phosphatase) staining was done on paraffin sections
from E14.5 mouse femurs as per manufactured protocol for Sigma
acid phosphatase kit (cat. 181A). A minimum of five male animals
were used from each genotype and stage unless stated otherwise.
Bone In Situ Hybridization (ISH)
E14.5 mouse femurs were fixed in 4% paraformaldhyde for 2
overnights at 4uC. 5 mm cryosections were dried for 2 hours to
overnight at room temperature. Slides were sequentially rinsed in
water, PBS an 2XSSC. Hybridization was at 65uC overnight in a
humidified chamber using 1 mg/ml dig-labeled probe. Post-
hybridization washes at 60uC were for 2610 minutes in 50%
formamide, 1XSSC, 0.1% tween-20, followed by 2610 minutes in
MABT and 30minutes with blocking buffer (20%goat serum,
20%BBR, 60% MABT). Anti-dig AP was added at 1:2000 and
incubated overnight at room temp. Color was revealed using
NTMT with NBT/BCIP and stopped with PBST. RNA probes
ColII and ColX were from Gerard Karsenty, Sox9 from Paul Sharpe
and Wise and Sost probes were generated from the 39UTR of a
mouse BAC containing genomic sequences from Wise and Sost that
were subcloned into pBluescript. A minimum of five animals were
used from each genotype and stage unless stated otherwise.
Skeletal Stain
Mouse P0 whole bodies were fixed in 4% paraformaldhyde for 2
overnights at 4uC, then into 95% ETOH for 7 days, and acetone
for 1 day. The mice were then stained in standard alizarin red/
alcian blue solution at 37uC for 3 days and rinsed in water. Then
cleared using 1%KOH for 1 day, and placed in a series of
increasing Glycerin (20%- 3 days, 50%- 4 days, 80%- 2 days)/1%
KOH until a final concentration of 100% Glycerin for 2 days is
achieved. A minimum of five animals were used for each genotype
and stage unless stated otherwise.
BrdU Proliferation Assay
BrdU (Sigma B-9285) was prepared in cold PBS at a
concentration of 1024M. The BrdU was injected into the nape
of the neck of newborn pups [2]. The pups were then terminated
after 2 hours. The tissue of interest was then dissected out and
fixed in 4% paraformaldhyde overnight at 4uC, then washed in
cold PBS. The samples were ETOH dehydrated, paraffin
embedded and sectioned at 5 um. Antigen retrieval used a Citrate
buffer and Biogenex EZ retriever microwave. Immunostaining
was automated using Biogenex and antibodies from Amersham. A
minimum of five animals were used for each genotype and stage
unless stated otherwise.
Calcein (Bone Formation Rate) Assay
Calcein (Sigma C-0875) was made up to a concentration of
2.5 mg/ml and injected on days 1 and 4, and terminated on day 6
[2]. The tissue was then dissected and fixed in 4% paraformald-
hyde overnight at 4uC. Paraffin embedded and processed at 7 um.
A minimum of five animals were used for each genotype and stage
unless stated otherwise.
Toluidine Blue Staining and von Kossa Stain
1 g Toluidine Blue (EM, CAS 92-31-9) was diluted in distillated
water then filtered [2]. Slides were incubated for 5–10 min then
rinsed in distillated water, dehydrated and cover-slipped. For von
Kossa staining, samples were fixed in 4% paraformaldhyde
overnight at 4uC, and then paraffin embedded and processed at
5 um. A 5% silver nitrate was used to stain slides in direct sunlight
for 10–20 minutes. The slides were then rinsed in water and then
the reaction stopped by the addition of 5% sodium thiosulphate
for 2–3 minutes. A minimum of five male animals were used for
each genotype and stage unless stated otherwise.
Histomorphometry
Osteomeasure software was used to accurately quantitate the
number of Toluidine Blue stained active osteoblasts and TRAP
positive osteoclasts from 1.5 month, 2.5 month or 4 month mouse
tibia long bone [2]. Six comparable slides containing two sections
within the middle of the tibia were used for each sample. A
distance of 800 um was analyzed from the growth plate into the
primary spongiosa. The bone formation rate was also quantified
using osteomeasure setting the time of injection to 4 days for the
metaphysis of the tibia long bone from a 1.5 month or 2.5 month
mouse. The trabecular bone volume was assessed in Von Kossa
stained using both mouse tibia long bones and L5 vertebrae from
tissues at 1.5 month, 2.5 month, and 4 month. Samples consisted
of a minimum of five male animals per genotype per stage unless
stated otherwise.
Animal Care and Usage
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocols were approved by the Institutional Animal Care and Use
Committees of the Stowers Institute for Medical Research (RK
Protocol ID: 2013-0110) and Washington University School of
Medicine (SS Protocol ID: 20120279). Animals were euthanized
by carbon dioxide consistent with the recommendations of the
Panel on Euthanasia of the American Veterinary Medical
Association, and all efforts were made to minimize suffering.
Results
In this study, to address the functional roles of Wise in vivo and
examine its relationship to Lrp5, we have generated a targeted null
mutation in the mouse gene by insertion of a selection cassette
following the signal sequence in exon 1 (Fig. 1A). The lacZ gene
inserted into the locus is not expressed. The effects of this targeted
mutation have been analyzed in both the 129 Sv/EV and
C57BL6 background strains. The comparison of the Wise mutants
within each strain, has revealed that in both strains, heterozygous
Wise+/2 mice are viable and fertile, and display no obvious
phenotypes. HomozygousWise2/2 mice are also viable and fertile,
however in the 129 Sv/EV strain litter sizes are often reduced and
there is a frequent increase in the number of resorptions. Postnatal
homozygous mutant animals display a number of distinct
phenotypes [25] [26], including changes in bone density which
are described in this study.
Wise Mutant Mice Display Increased Whole Body Bone
Mineral Density
In vitro assays suggest that Wise and Sclerostin have the potential
to inhibit Wnt signaling via a Lrp1, Lrp4, Lrp5 or Lrp6-dependent
mechanism, [19,20,23,29]. This potential, in combination with
bone density phenotypes in human SOST and LRP5 mutations, led
us to examine whether Wise participates in regulating bone mass.
We found a significant increase (p = 0.0017) in C57BL6 Wise2/2
whole body BMD over C57BL6 wildtype (n = 99), a difference that
was more pronounced than we observed when comparing
Wise/Lrp5 Regulates Bone Deposition
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Figure 1. Wise2/2Mutant Animals Display a High Bone Mass Phenotype. (A) Genomic structure of Wise. The Wise2/2mutant was created by
insertion of a neoLacZ cassette (red) into exon 1 at the SmaI site. Panel on the left illustrates Wise PCR based genotyping; genomic fragments are
generated for a wildtype band at 250 bp and a mutant band at 401 bp. (B) Whole body bone mineral density (BMD) measurements of the Wise2/2
mutant animals. Wise2/2 animals have a significant (p,0.05, asterisks) increase (7.5–11.6%) in bone density from between 1.5 to 3.0 months. At 4
months bone density normalized in Wise2/2mutant animal. Black bars represent wildtype, and white bars Wise2/2 mutants. (wildtype/mutant: N = 6/
6 1.5 m; N=3,3 2.5 m; N= 12,3 3 m; N=8,2 4 m). (C) Whole body mineral content (BMC) was increased significantly only at 2.5 months. No significant
changes in bone mineral content were observed at 1.5 months or at 3 months of age. Thus increases in bone mass seen at 1.5 & 3 m are not due to
significant increases in whole body bone mineral content. (wildtype/mutant: N = 6/6 1.5 m; N= 3/3 2.5 m; N= 12/3 3 m; N= 8/2 4 m). (D) To address
gross chondrocyte changes in the growth plate we measured the length of the tibia by X-ray. When compared to wildtype, the Wise2/2 mutant did
not display any significant difference in the length of the tibia. (wildtype/mutant: N = 5/4 1.5 m; N= 6/5 2.5 m; N=3/3 4 m). (E) Histomorphometry of
trabecular bone volume tabulated from von Kossa stained L5 vertebrae (equal results were obtained from Von Kossa stained long bones). Wise2/2
Wise/Lrp5 Regulates Bone Deposition
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129 Sv/EV Wise2/2 and wildtype 129 Sv/EV (n= 55) animals
(Data not shown, numbers reflect total animals between control
and test group). Because of the more severe phenotype in the
C57BL6 strain we chose to focus on this strain for a more detailed
analysis. C57BL6 Wise2/2 mutant mice have an increased whole
body bone mineral density (BMD) (7.5–11.6%) during the first 1.5
to 3 months of postnatal development (Fig. 1B). Interestingly, by 4
months of postnatal development the increase in bone density
normalizes in the Wise2/2 animals and is restored to strain
wildtype levels. This correlates with Beamer et al (1996) who
reported that bone density in various mice strains undergoes an
increase in bone deposition from 2 months (and possibly earlier) to
4 months, after which bone deposition appears to be at
equilibrium with bone resorption [33]. Thus Wise is acting as an
early (developmental) regulator of bone deposition. Coincident with
the initial increase in BMD observed using DEXA in Wise2/2
mutant animals there is a significant (p,0.05) increase in
trabecular bone volume at 1.5 and 2.5 months (Fig. 1E; asterisk)
as observed using histomorphometry. The increase in BMD in
Wise2/2 animals is not due to increases in bone mineral content
(BMC), as BMC values appear to be only significantly increased
in the Wise2/2 mutants at 2.5 months (Fig. 1C) observed using
DEXA. There is also no difference in tibia length (Fig. 1D), in
trabecular or cortical thickness (Fig. 1F) as observed using
histomorphometry, or whole body bone mineral density between
males and females (Fig. 1G) observed using DEXA. Hence in
Wise2/2 animals there is a significant transient increase in early
bone density.
Genetic Correction of Wise with LRP5 during
Mineralization
Consistent with changes in bone density, in C57BL6 Wise2/2
mutant animals, we observe an increased mineralization of
phalanges in both the fore and hindlimbs, which is clearly evident
in digits 4 and 5 (high power panels, asterisks, Fig. 2). This
phenotype is fully penetrant in both strains. This increased digit
mineralization phenotype is the opposite to that observed in both
Lrp52/2 and Lrp6+/2 mutant animals, which display a reduced
mineralization of the phalanges ([6,34] and Fig. 2). To determine
if the 129 Sv/EV Wise2/2 digit phenotype is also dependent upon
Lrp5, we generated Wise2/2;Lrp52/2 double mutant animals and
compared them with phenotypes in the single Lrp52/2 and
129 Sv/EV Wise2/2 mutants. Analysis of digits in Lrp52/2
mutant animals confirmed that there is a reduced mineralization
of phalanges at P0 (Fig. 2A and 2B) [6], although we find the
phenotype variable and not fully penetrant. In Wise2/2;Lrp52/2
double mutant animals, the increased mineralization seen in digits
of 129 Sv/EV Wise2/2 mutants is restored to near wildtype levels
or those seen in the single Lrp52/2 mutant animals (Fig. 2A and
2B). This demonstrates a genetic interaction between Wise and
Lrp5 in the digits and indicates that Lrp5 functions down-stream of
Wise in digit mineralization. This is also in agreement with the
model that Wise can function as a modulator of Wnt signaling via
its interactions with the Lrp5 or Lrp6 co-receptors. The Wise digit
phenotype may also be dependent upon Lrp6, as we have found
that Lrp6+/2 animals have an even more severe reduction in
mineralization of the phalanges (Fig. 2), similar to that seen in the
ringelschwanz Lrp6R886W/R886W homozygous animals. Our results
illustrate that both Lrp5 and Lrp6 play roles in regulating digit
ossification (Fig. 2). This is also consistent with published findings
that reveal dose-dependent phenotypes and variable penetrance in
double Lrp5/Lrp6 mutant combinations, indicating an epistatic
relationship between these two genes in a variety of tissue contexts
[35,36].
Temporally Dynamic Requirement for Wise in Regulating
Bone Formation
To investigate the cellular mechanisms that underlie the
increase in bone mass and its transient nature, we have examined
Wise expression during long bone development and used bone
specific markers to characterize changes in the C57BL6 Wise2/2
mutants. At E14.5 Wise mRNA is expressed in the mesenchymal
pre-osteoblasts (pOb) and periosteum, based on alkaline phospha-
tase (ALP) staining as a marker for late osteoblast matrix
deposition (Fig. 3A ). At E14 in mice Wise protein is excluded
from the hypertrophic chondrocytes but is found in active
osteoblasts lining the trabeculae and the proliferating chondrocytes
(Fig. 3B & E) conversly in avian at a slightly later stage pre-natally
(Hamburger and Hamilton Stage 44 ca. 18 days) Wise avian
protein can be detected in a subset of round proliferative
chondrocytes, flat proliferative chondrocytes, and hypertrophic
chondrocytes, but at 4 months of age it is no longer expressed in
the active osteoblast lineage (data not shown). Hence, Wise is
expressed by mesenchymal preosteoblasts during the early period
of bone formation; consistent with our results showing increased
bone density in the Wise2/2 mutants between 1.5 and 3.0 months
of age (Fig. 1B). At P0, Wise2/2 mutant animals have increased
ALP staining when compared to wildtype animals consistent with
increased BMD (Fig. 3C). Chondrocyte markers ColII, ColX, and
Sox9 staining show that the different chondrocyte layers, which are
present in wildtype, are also present in the Wise2/2 mutants
(Fig. 3C). However, the Wise2/2 has punctate staining of ColX
within the primary spongiosa, which is not present in wildtype
mice of similar strains.
The restoration of normal bone density after 4 months in the
Wise2/2 mutant animals correlates with the temporal loss of Wise
expression in the active osteoblast lineage. Hence, functional
compensation by other proteins might account for the transient
nature of the Wise BMD phenotype. In this regard, Wise is closely
related to the human protein Sclerostin (SOST), thus we have also
examined the expression of mouse Sost during bone development.
At E14.5 Sost is expressed in pre-osteoblast cells but not in active
osteoblasts (Fig. 3A). Conversely, at 4 months of age Sost is
expressed in both osteoblasts and osteocytes, while Wise expression
in the osteoblast lineage is absent (data not shown). Hence, Wise
and Sost are differentially expressed in osteoblast cells during
temporally distinct phases, whereby Wise is expressed early and
Sost later. Fig. 3D summarizes the timing of Wise and Sost
expression during chondrocyte and osteoblast differentiation.
These expression patterns are consistent with the late onset of
mutants (white bars) display a significant 1.3 to 1.5 fold increase over wildtype (black bars) in trabecular bone volume at 1.5 month and 2.5 month of
age. Increases of trabecular bone volume in Wise2/2 animals is normalized to wildtype levels. (wildtype/mutant: N = 6/6 1.5 m; N= 5,3 2.5 m). (F)
Histomorphometry of trabecular and cortical thickness of long bones. Wise2/2 mutant mice do not display a significant change, over wildtype, in
either trabecular or cortical thickness. (wildtype/mutant: trabecular N= 6/6, cortical N = 6/6 1.5 m; trabecular N= 5/3 2.5 m). (G) Comparison of bone
mineral density between males and females Wise2/2 mutants. There is no significant difference seen in the Wise2/2 mutants between the sexes at
either 1.5 month or at 2.5 months of age. (female/male: N= 3/3 1.5 m; N=4/3 2.5 m). Statistically significant (Student T-Tests, two tailed, p,0.05)
values are demarked by an asterisks.
doi:10.1371/journal.pone.0096257.g001
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increased bone density in human Sclerosteosis patients [37].
Hence, there is a strong correlation for both Wise and Sost between
the timing of their osteoblast gene expression and the onset of their
respective increased bone density phenotypes.
Wise Regulates Chondrocyte and Osteoblast Proliferation
The mineralization phenotype observed in C57BL6 Wise2/2
mutants and its genetic interaction with Lrp52/2 mutants imply
that Wnt signaling has been altered in chondrocytes and osteoblast
cells, therefore we analyzed these cell types from C57BL6 mice in
more detail (Fig. 4). Using BrdU labeling, we found that the
proliferation of the round proliferative chondrocytes is significantly
(p,0.05) decreased by 62% at P0, in the absence of Wise (Fig. 4A).
This is consistent with the idea that Wise acts as a positive
stimulator of Wnt signaling within the chondrocyte (Fig. 4E). In
contrast, active osteoblast proliferation is significantly increased by
2.9 fold at 1.5 months post-natally in the absence of Wise (Fig. 4B),
in agreement with its role as a Wnt antagonist in active osteoblasts
(Fig. 4E). The increase in trabecular osteoblast proliferation at 1.5
months assayed by BrdU incorporation is consistent with a
significant increase in the number of active osteoblasts as
quantified using Toluidine Blue staining (Fig. 4C). The increase
in trabecular osteoblast number and proliferation at 1.5 months
further correlates with a significant increase in trabecular bone
volume (Fig. 1E). To further investigate the potential link between
Wise and Wnt signaling in this context we generated Wise2/2
:Lrp52/2 mutants. We find that the increase in active trabecular
osteoblast numbers in Wise2/2 animals at 1.5 months is also
dependent upon the presence of Lrp5, as in double mutant animals
the numbers of active osteoblasts normalize to wild type levels
(Fig. 4C, hatched bar).
At 2.5 months post-natally, loss of Wise leads to a significant
decrease (58%) in the number of trabecular osteoclast cells
(Fig. 4C). This may be a consequence of an earlier increase in Wnt
signaling, osteoblasts and OPG levels, which negatively regulates
osteoclast differentiation [2]. At 2.5 months we also observe a
significant increase in trabecular bone volume (Fig. 1E) and 38%
increase in osteoblast bone formation rate (Fig. 4D). In summary,
our results suggests that Wise functions to regulate bone
development in multiple ways by modulating Wnt signaling in
Figure 2. Genetic Correction of Wise with Lrp5 during Ossification. (A) Skeletal stain at P0 showing hindlimb and forelimb phalange
development in the wildtype, Wise2/2, Lrp52/2, Wise2/2:Lrp52/2 and Lrp6+/2 strains. (B) Asterisks (*) highlight an increase in the ossification centers
of digits 4 and 5 of the hindlimb in Wise2/2 mutants compared to the other strains. This Wise2/2 mutant phenotype in digits is partially rescued in an
Lrp52/2 strain showing an epistatic relationship between Wise and Lrp5. n = at least 5.
doi:10.1371/journal.pone.0096257.g002
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Figure 3. Temporally Dynamic Requirement forWise during Bone Mass Regulation. (A) At E14.5 Wise is expressed in the mesenchymal pre-
osteoblasts and periosteum while Sost is only expressed in the pre-osteoblasts of the ulna. pOb, pre-osteoblasts. (B) Avian wise protein localization in
a prenatal embryonic Day 18 tibia (HH stage 44). Wise protein (FITC fluorescence coupled to the Wise primary peptide antibody) is found in the round
and a subset of flat proliferative chondrocytes (arrows) as well as pre-and hypertrophic chondrocytes. pCh; proliferating chondroctyes, rpCh; round
proliferative chondrocytes, fpCh; flat proliferative chondrocytes, phCh, prehypertrophic chondrocytes, hCh; hypertrophic chondrocytes. (C)
Comparing expression of bone specific markers between wildtype and Wise2/2 animals at P0. ALP appears to have increased staining in the Wise2/2
growth plate and primary spongiosa. ColII, ColX and Sox9 show no significant change in expression pattern in the Wise2/2 animals, when compared
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an Lrp-dependent manner that ultimately regulates the number of
chondrocytes, active trabecular osteoblasts and osteoclasts.
Discussion
In this study we demonstrate that Wise plays a fundamental role
in regulating early bone deposition through its ability to negatively
modulate Wnt signaling via interactions with the Lrp5 co-receptor.
Wise2/2 mutants display a significant (10%) increase in bone mass
at 1.5 months, due to increased proliferation of active osteoblasts.
This increase is dependent upon functional Lrp5, as Wise; Lrp5
double mutants have normal bone mass, implying this function is
mediated by activation of Wnt signaling in these cells. Further-
more, Wise has additional roles in bone formation outside of
osteoblast proliferation, as we found that it is required to
potentiate proliferation in chondrocytes as well. These findings
suggest that Wise has a role in fine-tuning Wnt signaling during
skeletal development through combined inputs on the control of
both osteoblastogenesis and chondrogenesis. Therefore, this work
provides important insight into mechanisms regulating the Wnt
pathway during the process of bone homeostasis.
Canonical Wnt Signaling and Bone Formation
Our analysis of Wise mutants, along with published studies of
Lrp5 and Axin2 mutants [6,38], reveal that these mutants all
display changes (an increase or decrease) in the number of actively
proliferating osteoblasts and possess corresponding bone formation
phenotypes. These analyses underscore the importance of Wnt
signaling in mechanisms regulating bone homeostasis via osteo-
blasts. Therefore, it is interesting that a loss of b-catenin does not
mimic the phenotypes seen in these three mutants [2,4,39].
Mutation of b-catenin affects bone resorption, as opposed to bone
formation, two very distinct aspects of bone homeostasis.
The absence of an effect on osteoblast proliferation in b-catenin
mutants is surprising because of the pivotal role b-catenin plays in
transducing canonical Wnt signaling. Modulation of Lrp5 or
soluble Wnt inhibitors like Wise may function to alter one of the
main inputs of Wnt signaling and control levels of output, but
there could be other inputs, for example mediated through Lrp6.
In contrast, because b-catenin plays such a critical role in
transducing canonical Wnt signaling, its absence would be
expected to have a more drastic affect on the relative levels of
activity. So how does one explain that the loss of b-catenin does not
lead to changes in osteoblast number as in Wise, Lrp5 and Axin2
mutant mice? It could be that the conditional b-catenin mouse
mutants were generated with drivers activated too late to give a
bone formation phenotype, and instead display only a bone
resorption phenotype. To resolve this issue, Rhodda and
McMahon (2006) examined a later inactivation of b-catenin and
have shown that this does indeed lead to an expansion of the
osteoblast cell population [40]. Thus it appears that the Wnt
pathway plays multiple roles during osteoblast specification and
also osteoblast population expansion.
Temporal Dynamics and Common Functions for Wise and
Sclerostin in Bone
This study demonstrates that in the bone Wise plays a key in vivo
role in modulating Wnt activity in an Lrp5-dependent manner.
The transient increase in bone density observed in Wise mutants
correlates with the expression of this gene in early active
osteoblasts lining the trabeculae. The increase in osteoblast
number and decrease in osteoclast number is reminiscent of
uncoupling bone resorption from bone formation [2]. The inverse
is seen for osteoblast numbers in a b-catenin [41] or an Lrp5 [6]
knockout which leads to a loss of osteoblast proliferation. Wnt
signalling has been reported to effect osteoblast proliferation, thus
one could hypothesize that a loss of Wnt signaling (as in the b-
catenin or Lrp5 null mutants) results in a loss of proliferation
whereas a gain in Wnt signaling (as in Wise mutants) would lead to
increased osteoblast proliferation.
Since we find that Wise is not expressed in osteoblasts or
osteocytes four months after birth, other factors or pathways acting
in a parallel or overlapping fashion may compensate for the loss of
Wise activity. Wise and Sost are duplicated and diverged genes that
encode a sub-family of cystein knot proteins with weak similarity to
the DAN and CCN sub-families. Our expression studies reveal
that Sost is not expressed in early active osteoblasts at the same
time as Wise, but it is expressed in later stages when Wise is absent.
In view of the sequence similarity between Wise and Sclerostin,
the differences in timing of expression and the evidence showing
that mutations of SOST in human and mouse result in high bone
density phenotypes, Sost is a likely candidate to compensate for the
loss of Wise in later stages of bone formation. Furthermore,
although loss of Wise function results in a 62% reduction in
hypertrophic chondrocyte proliferation, we interestingly observed
no differences in long bone length or body size. While one
explanation for this finding could be the lack of expression of Wise
by hypertrophic chondrocytes in mice, another more plausible
explanation could be because Sclerostin is still present in these
animals and has the ability to functionally compensate for the lack
of Wise. Using the same in vitro binding and Xenopus assays
employed to investigate the relationship between Wise and Wnt
signaling [19], we and others have found that Sost is also able to
inhibit various Wnt signaling ligands (Wnt1 and Wnt3a) through
interactions with Lrp1, Lrp4, Lrp5 or Lrp6 [20,23,42]. Therefore,
Sost, like Wise, has the potential to function as a negative regulator
of bone deposition by modulating Wnt signaling at later periods of
osteoblast maturation, when it is expressed. This suggests a model
whereby, Wise and Sost have common roles in regulation of bone
mass through the control of Wnt signaling and osteoblast
proliferation, although they act at different developmental stages.
This is consistent with the late onset of bone density phenotypes
observed in human mutations of SOST, presumably masked by the
earlier transient expression of Wise.
Unique Roles for Wise in Wnt Signaling and Bone
The characterization of changes in the rate of both osteoblast
and chondrocyte proliferation clearly revealed that Wise functions
in a different manner in these two cell types. In the osteoblast,
Wise normally serves to reduce or inhibit Wnt signaling, whereas
as in chondrocytes Wise may be acting to stimulate Wnt signaling.
to wildtype. Normal patterns of ALP (red), Col II (yellow), Col X (green), and Sox9 (blue) are shown in the bone schematic on the far left. (D) Model
integrating Sost and Wise expression during development of both chondrocytes and osteoblasts lineages. In this scheme Wise acts in early
osteoblasts while Sost functions later in mature osteoblasts and osteocytes. In chondrocytes, Wise and Sost appear to act both in the hypertrophic
chondrocyte. n = at least 5 in most cases. (E) In murine, at Prenatal embryonic day 14, Wise protein is also localized to a subset of proliferating
chondrocytes and active osteoblasts on the surface of the trabeculae in the ossification center (arrows) but not in the hypertrophic chondrocytes.
doi:10.1371/journal.pone.0096257.g003
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Figure 4. Characterization of the Osteoblast and Chondrocyte Phenotype in Wise2/2Mutants. (A) Chondrocyte proliferation as detected
using BrdU. P4 Wise2/2 mutants display a significant (asterisk) 63% decrease in proliferation of the round proliferative chondrocytes (rpCh), whereas
no significant change in the flat proliferative (fpCh), prehypertrophic (phCh), and hypertrophic chondrocytes (hCh). Black bars depict wildtype, white
bars depict Wise2/2. Insert shows the location of the different chondrocyte types within the long bone femur of a mouse. pCh; proliferating
chondrocytes. (N= 4 per group). (B) Active osteoblast cell proliferation as detected using BrdU in a 1.5 month mouse. Wise2/2 mutants display a
significant (asterisk) 2.9 fold increase in active osteoblast proliferation of long bones at 1.5 months. (N = 4 per group). (C) Active osteoblast/osteoclast
numbers counted from Toluidine Blue or Trap stained sections (Toluidine blue/Trap stained panel adjacent to chart) are quantified in Chart. A 2 fold
significant increase (asterisk) in active osteoblasts is seen in 1.5 month old Wise2/2 mutant long bones (arrow, blue columnar cells adjacent to
trabeculae in adjacent Toluidine Blue panel). This increase in active osteoblast numbers is dependent on the presence of Lrp5 as shown by the Chart
hatched bar at 1.5 month (Wise2/2;Lrp52/2). Osteoclast numbers (adjacent Trap stained panel (red), arrow) counted from TRAP stained sections
reveal a significant 58% decrease in numbers at 2.5 months of age in a Wise2/2 mutant. (wildtype/mutant: osteoblasts N= 6/6 1.5 m, N= 5/3 2.5 m;
osteoclasts N = 6/6 1.5 m, N= 5/3 2.5 m). (D) Bone formation rate as assayed from calcein double labeling. A significant (asterisk) 1.3 fold increase in
bone formation rate is evident in Wise2/2 mutant mice at 2.5 months of age. (N = 3 per group). (E) Summary of Wise Function. Wise functions as both
a stimulator and an inhibitor of Wnt signaling during skeletal development. In the chondrocytes, Wise acts as a positive stimulator of Wnt signaling,
whereas in the osteoblast, Wise functions as a Wnt antagonist. A loss of Wise function leads to an increase in bone mass at 1.5 to 2.5 months of age.
The increase in bone mass at 1.5 months of age is attributed to an increase in osteoblast Wnt signaling and hence osteoblast proliferation, resulting
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These opposing roles in Wnt signaling are consistent with our
previous analyses in Xenopus embryos, which suggested that Wise
has the potential to activate or inhibit Wnt signaling in a context-
dependent manner [19]. This differs from other cystein knot
family proteins, such as CTGF, Cyr61 and Sost, which also bind
Lrp1, Lrp5 or Lrp6 but only appear to be capable of inhibiting
Wnt signaling in Xenopus assays [20,43,44]. Hence, investigating
the mechanism by which Wise exerts this opposing influence on
Wnt signaling is important for understanding the control of
proliferation in osteoblasts versus chondrocytes. The basis for this
context-dependent shift in modulatory potential unique to Wise is
unknown. However, it could arise due to different sites of
interaction within the second YWTD propeller domain of the
LRPs and the cystein knot proteins or from differences in the
combination of specific LRP and frizzled co-receptors, Wnt
ligands and/or other co-factors (e.g. Dkk), all of which might alter
the conformation and stability of the signaling complex on the
membrane. Since Wise and Sost, are a sub-set of a large family of
cystein knot proteins, other members of this family (slits, mucins,
gremlin) may have previously unappreciated inputs into modula-
tion of Wnt signaling in bone formation, and could also influence
the specificity of protein interactions and signaling activity.
In summary, Wise functions in bone development. Our genetic
analyses with Wise and Lrp5 mutants demonstrate that the
biochemical interactions between Wise, Lrps and Wnt signaling
are functionally important in vivo in multiple aspects of bone
development. The genetic interaction with Lrp5 and increased
bone density phenotypes we observe in Wise2/2 mutant animals
highlights the key role that Lrps and Wnt signaling play in bone
homeostasis and illustrate the importance of extracellular modi-
fiers, such as Wise, in regulating this pathway.
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